Physician profile
Samuel N Marcus
NPI 1396717740
$1,547.11
in general payments reported to CMS, 2019-2025
15 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $18.05 · 2021: $32.72 · 2022: $67.96 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $360.32 | 2025 | Omvoh |
| Janssen Biotech, INC. | $296.97 | 2019-2025 | Tremfya |
| Abbvie INC. | $224.48 | 2021-2025 | |
| Celltrion USA INC. | $149.87 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $120.73 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.61 | 2019-2025 | Xifaxan |
| Pfizer INC. | $76.82 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.68 | 2019 | |
| Merck Sharp & Dohme LLC | $43.95 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $28.98 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $22.76 | 2025 | Suflave, Sutab |
| Pentax of America, INC. | $22.09 | 2022 | |
| Exact Sciences Corporation | $21.75 | 2025 | |
| W. L. Gore & Associates, INC. | $18.05 | 2020 | |
| Intercept Pharmaceuticals, INC. | $17.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.